Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.55 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144724 | 0.84 | MASP2 (0.46) | MASP2NAMPT | |
| SCHEMBL3149501 | 0.84 | ROCK2 (0.48) | MASP2NAMPT | |
| SCHEMBL3141278 | 0.84 | MASP2 (0.51) | MASP2F2NAMPT | |
| SCHEMBL8112583 | 0.83 | ERCC1 (0.50) | PRCPERCC1ERCC4DPP7DPP4 | |
| SCHEMBL3154431 | 0.83 | MASP2 (0.56) | MASP2NAMPT | |
| SCHEMBL1432088 | 0.82 | VNN1 (0.46) | VNN1PRCPMASP2F2 | |
| SCHEMBL3153097 | 0.81 | F2 (0.49) | MASP2F2 | |
| SCHEMBL3154324 | 0.81 | ROCK2 (0.48) | MASP2 | |
| SCHEMBL4312874 | 0.81 | VNN1 (0.55) | VNN1MASP2ERCC1ERCC4NOS1 | |
| SCHEMBL3144569 | 0.80 | NLN (0.60) | MASP2DPP4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | VNN1 3546/4885PRCP 1283/4885MASP2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.